Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of OTQ923 in Sickle Cell Disease
NCT06155500Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2024
- Primary completion
- Jan 2039
- Modality
- Gene Editing, Adoptive Cell Transfer, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OTQ923 in sickle cell disease (SCD), sponsored by Novartis. Primary endpoint: Number of participants with delayed adverse events that are suspected to be related to previous OTQ923 therapy at 15 years. Started Apr 2024; status: active, not recruiting.
02
Drugs
OTQ923
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06155500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06155500.